CVS Health Co. (NYSE:CVS) Shares Sold by New Hampshire Trust

New Hampshire Trust lessened its position in shares of CVS Health Co. (NYSE:CVS) by 21.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,332 shares of the pharmacy operator’s stock after selling 1,495 shares during the period. New Hampshire Trust’s holdings in CVS Health were worth $239,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. MidAtlantic Capital Management Inc. purchased a new stake in CVS Health during the 3rd quarter worth about $25,000. Ridgewood Investments LLC raised its position in shares of CVS Health by 255.7% during the 4th quarter. Ridgewood Investments LLC now owns 626 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 450 shares in the last quarter. Livelsberger Financial Advisory purchased a new stake in CVS Health during the third quarter worth approximately $31,000. Legacy Investment Solutions LLC purchased a new position in CVS Health in the third quarter valued at approximately $31,000. Finally, Reston Wealth Management LLC acquired a new stake in CVS Health during the third quarter worth approximately $32,000. 80.66% of the stock is owned by hedge funds and other institutional investors.

CVS Health Trading Up 1.5 %

Shares of CVS stock opened at $52.72 on Tuesday. The stock has a market cap of $66.35 billion, a P/E ratio of 13.38, a P/E/G ratio of 0.79 and a beta of 0.59. The company has a quick ratio of 0.59, a current ratio of 0.80 and a debt-to-equity ratio of 0.80. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The business has a fifty day simple moving average of $51.34 and a 200-day simple moving average of $56.32.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.01. The firm had revenue of $95.43 billion during the quarter, compared to the consensus estimate of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. The firm’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same period last year, the firm posted $2.21 EPS. On average, analysts forecast that CVS Health Co. will post 5.22 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 5.05%. The ex-dividend date of this dividend is Thursday, January 23rd. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on CVS. Truist Financial decreased their price objective on shares of CVS Health from $67.00 to $60.00 and set a “buy” rating for the company in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $62.00 price target on shares of CVS Health in a research report on Tuesday, October 1st. Barclays cut their target price on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating on the stock in a report on Thursday, November 7th. Royal Bank of Canada decreased their price target on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research note on Friday, November 15th. Finally, Wells Fargo & Company upgraded shares of CVS Health from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $60.00 to $66.00 in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $68.71.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.